Plasma protein binding of cannabidiol
- PMID: 35304781
- DOI: 10.1002/ptr.7443
Plasma protein binding of cannabidiol
References
REFERENCES
-
- Babayeva, M., Assefa, H., Basu, P., Chumki, S., & Loewy, Z. (2016). Marijuana compounds: A non-conventional approach to Parkinson's disease therapy. Parkinsons Dis, 2016, 1279042.
-
- Babayeva, M., Assefa, H., Basu, P., & Loewy, Z. (2022). Autism and associated disorders: Cannabis as a potential therapy. Frontiers in Bioscience (Elite Edition), 14(1), 001.
-
- Bansal, S., Maharao, N., Paine, M. F., & Unadkat, J. D. (2020). Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metabolism and Disposition, 48(10), 1008-1017.
-
- Burstein, S. (2015). Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorganic & Medicinal Chemistry, 23, 1377-1385.
-
- Celestin, M. N., & Musteata, F. M. (2021). Impact of changes in free concentrations and drug-protein binding on drug dosing regimens in special populations and disease states. Journal of Pharmaceutical Sciences, 110(10), 3331-3344.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources